Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial. / Kjølbæk, Louise; Benítez-Páez, Alfonso; Gómez Del Pulgar, Eva M; Brahe, Lena Kirchner; Liebisch, Gerhard; Matysik, Silke; Rampelli, Simone; Vermeiren, Joan; Brigidi, Patrizia; Larsen, Lesli Hingstrup; Astrup, Arne; Sanz, Yolanda.
I: Clinical Nutrition, Bind 39, Nr. 1, 2020, s. 67-79.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial
AU - Kjølbæk, Louise
AU - Benítez-Páez, Alfonso
AU - Gómez Del Pulgar, Eva M
AU - Brahe, Lena Kirchner
AU - Liebisch, Gerhard
AU - Matysik, Silke
AU - Rampelli, Simone
AU - Vermeiren, Joan
AU - Brigidi, Patrizia
AU - Larsen, Lesli Hingstrup
AU - Astrup, Arne
AU - Sanz, Yolanda
N1 - Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background & aims: Gut microbiota composition is linked to obesity and metabolic syndrome. The nutrients and doses required to modulate the gut microbiota towards beneficially influence components of the metabolic syndrome are unclear. This study aimed to investigate diet-induced effects on the gut microbiota and metabolic markers in overweight individuals with indices of the metabolic syndrome.Methods: A twelve-week randomized cross-over trial was conducted with two intervention periods separated by a washout period. The dietary intakes of interest were wheat bran extract, rich in arabinoxylan oligosaccharides (AXOS) (10.4 g/d AXOS) and polyunsaturated fatty acids (PUFA) (3.6 g/d n-3 PUFA). Dietary records, fecal and blood samples, as well as anthropometric data, were collected before and after intervention. Anthropometry and gastrointestinal symptoms were evaluated weekly. Gut microbiota composition was analyzed by massive sequencing of 16S ribosomal RNA gene V3V4 amplicons.Results: Twenty-seven participants completed the study (90%). Intake of AXOS induced an expected bifidogenic effect on gut microbiota (p < 0.01) and increased butyrate-producing bacterial species as well (p < 0.05). Beta-diversity analysis indicated that the structure of the gut microbiota only changed as a result of the AXOS intervention (Permanova = 1.90, p < 0.02) and no changes in metabolic markers were observed after any of the interventions.Conclusions: AXOS intake has a bifidogenic effect and also increases butyrate producers in the gut microbiota; even though this type of dietary fiber did not modulate lipid or glucose metabolic parameters related to metabolic syndrome. Four-week PUFA intake did not induce any notable effect on the gut microbiota composition or metabolic risk markers.Registration: Registered under ClinicalTrials.gov Identifier no. NCT02215343.Clinical trial registration: Registered at https://www.clinicaltrials.gov/ (NCT02215343).Ethical Committee: H-4-2014-052.The Danish Data Protection Agency: 2013-54-0522.
AB - Background & aims: Gut microbiota composition is linked to obesity and metabolic syndrome. The nutrients and doses required to modulate the gut microbiota towards beneficially influence components of the metabolic syndrome are unclear. This study aimed to investigate diet-induced effects on the gut microbiota and metabolic markers in overweight individuals with indices of the metabolic syndrome.Methods: A twelve-week randomized cross-over trial was conducted with two intervention periods separated by a washout period. The dietary intakes of interest were wheat bran extract, rich in arabinoxylan oligosaccharides (AXOS) (10.4 g/d AXOS) and polyunsaturated fatty acids (PUFA) (3.6 g/d n-3 PUFA). Dietary records, fecal and blood samples, as well as anthropometric data, were collected before and after intervention. Anthropometry and gastrointestinal symptoms were evaluated weekly. Gut microbiota composition was analyzed by massive sequencing of 16S ribosomal RNA gene V3V4 amplicons.Results: Twenty-seven participants completed the study (90%). Intake of AXOS induced an expected bifidogenic effect on gut microbiota (p < 0.01) and increased butyrate-producing bacterial species as well (p < 0.05). Beta-diversity analysis indicated that the structure of the gut microbiota only changed as a result of the AXOS intervention (Permanova = 1.90, p < 0.02) and no changes in metabolic markers were observed after any of the interventions.Conclusions: AXOS intake has a bifidogenic effect and also increases butyrate producers in the gut microbiota; even though this type of dietary fiber did not modulate lipid or glucose metabolic parameters related to metabolic syndrome. Four-week PUFA intake did not induce any notable effect on the gut microbiota composition or metabolic risk markers.Registration: Registered under ClinicalTrials.gov Identifier no. NCT02215343.Clinical trial registration: Registered at https://www.clinicaltrials.gov/ (NCT02215343).Ethical Committee: H-4-2014-052.The Danish Data Protection Agency: 2013-54-0522.
KW - Faculty of Science
KW - Gut microbiota
KW - Arabinoxylan oligosaccharide
KW - Fiber
KW - Fish oil
KW - Metabolic syndrome
KW - Obesity
U2 - 10.1016/j.clnu.2019.01.012
DO - 10.1016/j.clnu.2019.01.012
M3 - Journal article
C2 - 30827722
VL - 39
SP - 67
EP - 79
JO - Clinical Nutrition
JF - Clinical Nutrition
SN - 0261-5614
IS - 1
ER -
ID: 214335307